Open-Source Alzheimer's Research

Scientists Reversed Alzheimer's in Mice. We're Building the Bridge.

The gap between a mouse study and a human therapy isn't just biology — it's tooling. We build AI infrastructure backed by 20+ peer-reviewed bio papers at NeurIPS, AAAI & Stanford. Mission-driven. Peer-reviewed. Built to last.

Explore the AI Toolkit Read the Science

"My mother died from Alzheimer's. My sister was diagnosed 18 months ago. This isn't a research interest — it's a race against the clock I can hear ticking in every phone call home."

David Scott Lewis

Founder, The Reversal Initiative · Former META EVP · AI Researcher Since the 1990s · 20+ Peer-Reviewed Bio Papers

What We Build

Three Pillars of Open Drug Discovery

Every tool we build is peer-reviewed, and designed so any lab on Earth can use it — not just those with billion-dollar budgets.

SCREEN Targets

AI-driven target identification across the NAD+ biosynthesis pathway. Our models evaluate binding affinity, selectivity, and blood-brain barrier penetration to prioritize the most promising intervention points.

BUILD Molecules

Generative chemistry pipelines that design novel neuroprotective compounds. Each candidate is optimized for drug-likeness, synthesizability, and predicted efficacy against validated Alzheimer's mechanisms.

VERIFY Safety

Multi-scale toxicity prediction before any compound reaches a living cell. Off-target binding, hepatotoxicity, cardiotoxicity, and mutagenicity are all flagged computationally — reducing animal testing and accelerating timelines.

Peer-Reviewed Breakthrough

P7C3-A20 Reverses Alzheimer's Pathology in Mice

David Scott Lewis presenting the Cell Reports Medicine Alzheimer's reversal paper at AAAI-26 Singapore Expo — **Cell Reports Medicine · January 2026** — David discussing the foundational Alzheimer's paper by Chauhan, Vázquez-Rosa et al. at AAAI-26, Singapore Expo — authors: Case Western Reserve University, Johns Hopkins, Seoul National University.

Published in Cell Reports Medicine (2025), researchers demonstrated that the P7C3-A20 compound — an NAD+ pathway activator — reversed cognitive decline, reduced amyloid plaques, and restored synaptic function in Alzheimer's mouse models. This is the foundational biology our AI tools are built to accelerate.

DOI: 10.1016/j.xcrm.2025.102535

⚠ Authors: Chauhan, Vázquez-Rosa et al., Case Western Reserve University et al. — This paper is not authored by AIXC. It is the foundational discovery our computational platform is built to build upon and accelerate.

Traction

Where This Work Stands

AAAI-26 Oral

Accepted for oral presentation at the premier AI conference · Google Scholar Top 3 ranked

NeurIPS Workshop

AI for Drug Discovery workshop with peer review · Google Scholar Top 3 ranked

Stanford Collab

Methodology validated by Stanford computational biology group

ICLR 2026 (~14 Papers)

Accepted at the #2 ranked AI conference (Google Scholar). Publishing alongside Google DeepMind and OpenAI.

2 Drug Programs

Tools actively used in commercial drug discovery pipelines

20+ Peer-Reviewed Bio Papers

Bio-focused research published at AAAI, NeurIPS, Stanford — drug discovery, toxicology, protein structure, genomics

AI Research Since the 1990s

Founded by David Scott Lewis, AI researcher with nearly three decades of pioneering experience

Research Credibility

20+ Bio Papers at World-Class Venues

Our Alzheimer's and bio research validated at the same conferences where Google DeepMind, Genentech, and Stanford publish. Our founder has been an AI researcher since the 1990s.

AAAI-26

Drug discovery & Alzheimer's AI — AIDD & LMReasoning workshops. 1 oral presentation.

#4 Google Scholar · h5-index 212

Top AI conference since 1979. Same stage as OpenAI, DeepMind & Stanford AI Lab. 17,000+ researchers attend.

Official AAAI site →

ICLR 2026

Biomedical AI, drug discovery & world models workshops.

#2 Google Scholar · h5-index 304

World's premier deep learning conference. Fully open peer-review. Where Google Brain, Meta FAIR & Genentech AI publish.

Official ICLR site →

NeurIPS

AI for Drug Discovery Workshop — computational biology focus.

#1 Google Scholar · h5-index 337

The world's most-cited AI conference. 15,000+ submissions, ~25% acceptance. Every major AI lab on Earth publishes here.

AI4D3 Drug Discovery Workshop →

MLGenX

Generative AI for molecular drug discovery — Alzheimer's targets.

ICLR-affiliated · inherits #2 world ranking

Workshop at ICLR 2026 focused on generative AI for experimental sciences and molecular discovery.

MLGenX workshop →

AI4X-AC

Applied AI for science — 2 oral presentations on Alzheimer's & cancer.

Peer-reviewed AI × Science

International AI for Science conference held in Ljubljana, Slovenia. Bridges AI with biology, chemistry & medicine. Rigorous peer review.

Conference site →

ELLIS

ML4Molecules Workshop — molecular drug discovery.

Europe's top AI research network

European Laboratory for Learning & Intelligent Systems — Europe's equivalent to MIT's AI Lab. Members include Yoshua Bengio (Turing Award).

ML4Molecules workshop →

Stanford

Agents4Science Workshop — AI agents for scientific discovery.

Stanford University · Nobel laureate advisory

Hosted by Stanford University, one of the world's top research institutions. Workshop on autonomous AI scientists — the frontier of AI-driven discovery.

Stanford site →

Publishing alongside: Google DeepMind OpenAI Meta FAIR Microsoft Research Stanford MIT CMU

AAAI OpenReview Stanford Agents4Science NeurIPS AI4D3 Stanford Paper AAAI AIDD AAAI AI4Research

4 oral presentations — fewer than 2% of submissions receive this honor